M. Ratajska

发表

Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects

R. Kaliszan, M. Stukan, M. Markuszewski, 2019, PloS one.

Mutational analysis of BRCA 1 / 2 in a group of 134 consecutive ovarian cancer patients . Novel and recurrent BRCA 1 / 2 alterations detected by next generation sequencing

Å. Borg, M. Stukan, J. Limon, 2015 .

Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing

Å. Borg, M. Stukan, J. Limon, 2014, Journal of Applied Genetics.

Concurrent DNA Copy‐Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients

A. Piotrowski, A. Bogdan, Rafał Bartoszewski, 2015, Human mutation.

The Angiotensinogen AGT p.M235T Gene Polymorphism May Be Responsible for the Development of Severe Anaphylactic Reactions to Insect Venom Allergens

E. Jassem, J. Limon, M. Ratajska, 2010, International Archives of Allergy and Immunology.

Detection of somatic BRCA1/2 mutations in ovarian cancer – next‐generation sequencing analysis of 100 cases

J. Limon, M. Lewandowska, W. Biernat, 2016, Cancer medicine.

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients

M. Stukan, P. Kozłowski, J. Limon, 2018, Cancers.

Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases

M. Dąbrowska, A. Kluska, A. Bałabas, 2012, Familial Cancer.

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

M. Stukan, J. Limon, M. Ratajska, 2008, Gynecologic oncology.

Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe

T. Dörk, E. Khusnutdinova, P. Hillemanns, 2014, Familial Cancer.

Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures

C. Print, M. Eccles, J. Ryś, 2022, Frontiers in Immunology.

Loss of heterozygosity atBRCA1/2 loci in hereditary and sporadic ovarian cancers

M. Stukan, J. Limon, M. Ratajska, 2010, Journal of Applied Genetics.

Spectrum of NIPBL gene mutations in Polish patients with Cornelia de Lange syndrome

M. Malinowska, J. Limon, J. Wierzba, 2013, Journal of applied genetics.

Spectrum of NIPBL gene mutations in Polish patients with Cornelia de Lange syndrome

M. Malinowska, J. Limon, J. Wierzba, 2012, Journal of Applied Genetics.

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases

P. Kozłowski, M. Ratajska, M. Suszyńska, 2020, Journal of Ovarian Research.

Cancer predisposing BARD1 mutations in breast–ovarian cancer families

Å. Borg, A. Piskorz, J. Limon, 2011, Breast Cancer Research and Treatment.

Genetic predisposition to breast and/or ovarian cancer– focus on the candidate BARD1 gene

P. Kozłowski, M. Ratajska, M. Wojciechowska, 2015 .

Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases

M. Dąbrowska, A. Kluska, A. Bałabas, 2012, Familial Cancer.

Prevalence of the most frequent BRCA1 mutations in Polish population

Danuta Januszkiewicz-Lewandowska, M. Dąbrowska, A. Kluska, 2011, Journal of Applied Genetics.

BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.

Å. Borg, J. Jassem, G. Palmieri, 2008, Oncology reports.

BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation

T. Dörk, N. Bogdanova, A. Jakubowska, 2019, Cancers.

Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability

I. Irminger-Finger, G. Laurent, J. Limon, 2016, Oncotarget.

New concepts on BARD1: Regulator of BRCA pathways and beyond.

I. Irminger-Finger, M. Ratajska, M. Pilyugin, 2016, The international journal of biochemistry & cell biology.

Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.

I. Irminger-Finger, G. Laurent, P. Kozłowski, 2015, Oncology reports.

Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example

I. Irminger-Finger, M. Stukan, P. Kozłowski, 2015, Scientific Reports.

Cancer predisposing BARD 1 mutations affect exon skipping and are associated with overexpression of specific BARD 1 isoforms

I. Irminger-Finger, G. Laurent, P. Kozłowski, 2015 .

The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer

Joseph Cursons, C. Curtis, Bum-Kyu Lee, 2021, Nature Communications.

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer

M. Stukan, J. Limon, W. Biernat, 2017, Oncotarget.

Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe

T. Dörk, E. Khusnutdinova, P. Hillemanns, 2015, Familial Cancer.

HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours

M. Stukan, J. Limon, M. Ratajska, 2006, Hereditary cancer in clinical practice.

Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer

J. Jassem, M. Best, T. Würdinger, 2021, Cancers.

Differential Expression of BARD1 Isoforms in Melanoma

M. Eccles, G. Reid, L. Walker, 2021, Genes.

The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population

A. Jakubowska, J. Lubiński, P. Kozłowski, 2017, Oncotarget.

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

R. Dziadziuszko, J. Jassem, A. Szczesna, 2016, Oncotarget.

Cancer predisposing BARD1 mutations in breast-ovarian cancer families

M. Stukan, J. Limon, M. Matusiak, 2012, Hereditary Cancer in Clinical Practice.

Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer.

M. Eccles, L. Walker, A. Jasiak, 2023, Experimental and molecular pathology.

A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients.

M. Stukan, J. Limon, E. Kreimann, 2015, Oncology letters.

Erratum to: Spectrum of NIPBL gene mutations in Polish patients with Cornelia de Lange syndrome

M. Malinowska, J. Limon, J. Wierzba, 2013, Journal of Applied Genetics.

ovarian cancer in a family with coexistence of germline nf1 and brca1 mutations case report

J. Limon, Magdalena Koczkowska, Alina Kuźniacka, 2018 .

A. Jakubowska, J. Lubiński, P. Kozłowski, 2017, Oncotarget.

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients

M. Stukan, P. Kozłowski, J. Limon, 2018, Cancers.

Cornelia de Lange syndrome case due to genomic rearrangements including NIPBL.

P. Stankiewicz, Z. Xia, J. Lupski, 2010, European journal of medical genetics.

New concepts on BARD1: Regulator of BRCA pathways and beyond.

M. Ratajska, I. Irminger‐Finger, Maxim Pilyugin, 2016, The international journal of biochemistry & cell biology.

Concurrent DNA Copy‐Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients

A. Piotrowski, A. Bogdan, Rafał Bartoszewski, 2015, Human mutation.